Hepatitis C Topics Side Effects - HCV
Hard-to-Treat Hepatitis C Patients Relapse after Stopping Interferon-Free GS-7977/Ribavirin Regimen
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 21 February 2012 00:00
- Written by Liz Highleyman
A majority of prior null responders with difficult-to-treat hepatitis C virus (HCV) genotype 1 experienced viral rebound after completing treatment with an all-oral regimen of the HCV nucleotide polymerase inhibitor GS-7977 plus ribavirin.
Managing Side Effects of New Hepatitis C Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Tuesday, 14 February 2012 00:00
- Written by Liz Highleyman
Adding the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek) to pegylated interferon plus ribavirin can shorten the course of treatment and increase the likelihood of a cure, but can also lead to more adverse events. Fortunately, side effects are typically mild-to-moderate and usually can be managed without stopping therapy, according to a recent review.
Updated PegIntron Label Psychiatric Warning
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 14 June 2011 07:41
- Written by Press Release
Package information for Intron-A conventional interferon and PegIntron pegylated interferon were updated with a warning that people with psychiatric and substance use disorders may experience worse symptoms. 
Coffee Helps Reduce Side Effects in HIV/HCV Coinfected People during Interferon-based Therapy
- Details
- Category: HCV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people who drink at least 3 cups of coffee daily were less likely to experienced adverse events related to interferon-based therapy for hepatitis C, according to a French study presented at the 10th AIDS Impact Conference last month in Santa Fe. However, whether coffee somehow directly relieves side effects remains unknown.
Anemia during Hepatitis C Treatment Predicts Sustained Response to Pegylated Interferon/ribavirin
- Details
- Category: Anemia & Neutropenia
- Published on Monday, 10 January 2011 16:00
- Written by Liz Highleyman
Hepatitis C patients who develop anemia during treatment with pegylated interferon plus ribavirin are more likely to achieve a sustained virological response (SVR), according to data from the IDEAL trial published in the November 2010 issue of Gastroenterology. Both ribavirin dose reduction -- which did not decrease SVR -- and medications that stimulate red blood cell production may be used to manage anemia and help people stay on treatment, the study authors concluded. 
